GED-0301
Sponsors
Celgene
Conditions
Colitis, UlcerativeCrohn DiseaseCrohn's DiseaseHealthy Volunteers
Phase 1
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
CompletedNCT02367183
Start: 2015-04-08End: 2017-12-14Updated: 2019-01-10
A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects
CompletedNCT02957474
Start: 2016-11-30End: 2016-12-31Updated: 2017-01-12
Phase 2
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
CompletedNCT02601300
Start: 2015-12-14End: 2017-08-08Updated: 2018-10-17
Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease
TerminatedNCT02685683
Start: 2016-04-04End: 2017-11-09Updated: 2018-08-14
Phase 3
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
TerminatedNCT02596893
Start: 2015-12-08End: 2018-01-05Updated: 2019-08-28
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
TerminatedNCT02641392
Start: 2016-07-25End: 2018-01-04Updated: 2019-01-29
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
WithdrawnNCT02974322
Start: 2017-12-01End: 2018-12-24Updated: 2017-11-14